# Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium

> **NCT04221802** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 76 (actual)

## Conditions studied

- Severe Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04221802
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-23
- **Primary completion:** 2024-05-13
- **Final completion:** 2024-05-13
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221802, "Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04221802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*